Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.

Emma C. Hulshof,Femke M. de Man,Geert-Jan Creemers,Birgit A.L.M. Deiman,Jesse J. Swen,Saskia Houterman,Stijn L.W. Koolen,Marjan Laven,Saskia A.C. Luelmo,Ron H.N. van Schaik,Henk-Jan Guchelaar,Ron H.J. Mathijssen,Hans Gelderblom,Maarten J. Deenen

Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.

2021

Emma C. Hulshof
Femke M. de Man
Geert-Jan Creemers
Birgit A.L.M. Deiman
Jesse J. Swen
Saskia Houterman
Stijn L.W. Koolen
Marjan Laven
Saskia A.C. Luelmo
Ron H.N. van Schaik
Henk-Jan Guchelaar
Ron H.J. Mathijssen
Hans Gelderblom
Maarten J. Deenen

3574Background: Irinotecan is commonly used in the treatment of advanced colorectal and pancreatic cancer. The polymorphisms UGT1A1*28 (7 TA repeats) and UGT1A1*93 (SNP -3156G > A) are significantl...

Keywords:

Pancreatic cancer
Internal medicine
pharmacokinetic analysis
Medicine
Oncology
SNP
Irinotecan
Dosing
Genotype

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations